Understanding of dopant-induced osteogenesis and angiogenesis in calcium phosphate ceramics

Trends in Biotechnology

Volumn 31, Issue 10, 2013, Pages 594-605

  Bose, Susmita ^a   Fielding, Gary ^a   Tarafder, Solaiman ^a   Bandyopadhyay, Amit ^a  

^a Washington State University   (United States)

Author keywords

Angiogenesis; Bone remodeling; Calcium phosphates; Dopants or trace metal ions; Osteogenesis

Indexed keywords

ANGIOGENESIS; BONE REMODELING; CALCIUM PHOSPHATE CERAMICS; CLINICAL APPLICATION; NEO-VASCULARIZATION; OSTEOGENESIS; OSTEOINDUCTIVE PROPERTIES; TRACE METAL IONS;

BIOLOGICAL MATERIALS; BIOMATERIALS; BONE; CERAMIC MATERIALS; DOPING (ADDITIVES); METAL IONS;

CALCIUM PHOSPHATE;

BORON; CALCIUM PHOSPHATE CERAMIC; CALCIUM SENSING RECEPTOR; COBALT; CUPROUS ION; DIVALENT CATION; HYDROXYAPATITE; LITHIUM ION; MAGNESIUM ION; MANGANESE; METAL ION; MONOVALENT CATION; OSTEOCLAST DIFFERENTIATION FACTOR; SILICON; STRONTIUM; TRACE METAL; VASCULOTROPIN; ZINC ION; ZINC PHOSPHATE;

ANGIOGENESIS; BIOMINERALIZATION; BONE DENSITY; BONE DEVELOPMENT; BONE GROWTH; BONE REGENERATION; BONE STRENGTH; BONE TISSUE; BONE TRANSPLANTATION; BONE TURNOVER; CELL DIFFERENTIATION; CELL MIGRATION; FRACTURE HEALING; HUMAN; ORTHOPEDIC IMPLANT; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SAFETY; TISSUE ENGINEERING;

ANGIOGENESIS; BONE REMODELING; CALCIUM PHOSPHATES; DOPANTS OR TRACE METAL IONS; OSTEOGENESIS;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE REMODELING; CALCIUM PHOSPHATES; CERAMICS; HUMANS; METALS; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOGENESIS; TISSUE ENGINEERING;

EID: 84884352725     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.06.005     Document Type: Review

References (101)

1. Bose S., Tarafder S. Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review. Acta Biomater. 2012, 8:1401-1421.
2. Carano R.A.D., Filvaroff E.H. Angiogenesis and bone repair. Drug Discov. Today 2003, 8:980-989.
3. Gerber H.P., Ferrara N. Angiogenesis and bone growth. Trends Cardiovasc. Med. 2000, 10:223-228.
4. Geiger M. Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug Deliv. Rev. 2003, 55:1613-1629.
5. Tamai N., et al. A new biotechnology for articular cartilage repair: subchondral implantation of a composite of interconnected porous hydroxyapatite, synthetic polymer (PLA-PEG), and bone morphogenetic protein-2 (rhBMP-2). Osteoarthritis Cartilage 2005, 13:405-417.
6. Shields L.B.E., et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006, 31:542-547.
7. Boraiah S., et al. Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report. Clin. Orthop. Relat. Res. 2009, 467:3257-3262.
8. Luca L., et al. The effects of carrier nature and pH on rhBMP-2-induced ectopic bone formation. J. Control. Release 2010, 147:38-44.
9. 2 dopants. J. Am. Ceram. Soc. 2006, 89:2675-2688.
10. Li X., et al. The optimum zinc content in set calcium phosphate cement for promoting bone formation in vivo. Mater. Sci. Eng. C: Mater. Biol. Appl. 2009, 29:969-975.
11. Bohner M. Silicon-substituted calcium phosphates-a critical view. Biomaterials 2009, 30:6403-6406.
12. 2 and ZnO doping on mechanical and biological properties of 3D printed TCP scaffolds. Dent. Mater. 2012, 28:113-122.
13. Hanai Y., et al. Up-regulation by zinc of FGF-2-induced VEGF release through enhancing p44/p42 MAP kinase activation in osteoblasts. Life Sci. 2006, 80:230-234.
14. Gao T., et al. Silica-based bioactive glasses modulate expression of bone morphogenetic protein-2 mRNA in Saos-2 osteoblasts in vitro. Biomaterials 2001, 22:1475-1483.
15. Mouriño V., et al. Metallic ions as therapeutic agents in tissue engineering scaffolds: an overview of their biological applications and strategies for new developments. J. R. Soc. Interface 2011, 10.1098/rsif.2011.0611.
16. Lakhkar N.J., et al. Bone formation controlled by biologically relevant inorganic ions: role and controlled delivery from phosphate-based glasses. Adv. Drug Deliv. Rev. 2013, 65:405-420.
17. Habibovic P., Barralet J.E. Bioinorganics and biomaterials: bone repair. Acta Biomater. 2011, 7:3013-3026.
18. Matsumoto N., et al. Thermal stability of β-tricalcium phosphate doped with monovalent metal ions. Mater. Res. Bull. 2009, 44:1889-1894.
19. Lehmann S.W., Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know?. J. Affect. Disord. 2012, 10.1016/j.jad.2012.08.028.
20. Marti J.L., et al. Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann. Surg. Oncol. 2012, 19:3465-3471.
21. Zamani A., et al. Lithium's effect on bone mineral density. Bone 2009, 44:331-334.
22. Chalecka-Franaszek E., Chuang D.-M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8745-8750.
23. Hedgepeth C.M., et al. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev. Biol. 1997, 185:82-91.
24. Chen Y., et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoS Med. 2007, 4:e249.
25. Monroe D.G., et al. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012, 492:1-18.
26. Milat F., Ng K.W. Is Wnt signalling the final common pathway leading to bone formation?. Mol. Cell. Endocrinol. 2009, 310:52-62.
27. Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 2013, 19:179-192.
28. Lin G.L., Hankenson K.D. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J. Cell. Biochem. 2011, 112:3491-3501.
29. Zhang R., et al. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 2013, 52:145-156.
30. Wang J., et al. Electrolytic deposition of lithium into calcium phosphate coatings. Dent. Mater. 2009, 25:353-359.
31. Fielding G.A., et al. Antibacterial and biological characteristics of plasma sprayed silver and strontium doped hydroxyapatite coatings. Acta Biomater. 2012, 8:3144-3152.
32. Yamaguchi M. Role of nutritional zinc in the prevention of osteoporosis. Mol. Cell. Biochem. 2009, 338:241-254.
33. Hadley K.B., et al. Dietary zinc reduces osteoclast resorption activities and increases markers of osteoblast differentiation, matrix maturation, and mineralization in the long bones of growing rats. J. Nutr. Biochem. 2010, 21:297-303.
34. Yamaguchi M., Weitzmann M.N. Zinc stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation. Mol. Cell. Biochem. 2011, 355:179-186.
35. Ito A., et al. Zinc-releasing calcium phosphate for stimulating bone formation. Mater. Sci. Eng. C 2002, 22:21-25.
36. Rude R.K., et al. Dietary magnesium reduction to 25% of nutrient requirement disrupts bone and mineral metabolism in the rat. Bone 2005, 37:211-219.
37. Maier J.A., et al. High concentrations of magnesium modulate vascular endothelial cell behaviour in vitro. Biochim. Biophys. Acta 2004, 1689:6-12.
38. Cooke J.P., Losordo D.W. Nitric oxide and angiogenesis. Circulation 2002, 105:2133-2135.
39. Zou L. Lasting controversy on ranibizumab and bevacizumab. Theranostics 2011, 1:395-402.
40. Stendig-Lindberg G., et al. Experimentally induced prolonged magnesium deficiency causes osteoporosis in the rat. Eur. J. Intern. Med. 2004, 15:97-107.
41. Xue W., et al. Synthesis and characterization of tricalcium phosphate with Zn and Mg based dopants. J. Mater. Sci. Mater. Med. 2008, 19:2669-2677.
42. Landi E., et al. Biomimetic Mg-substituted hydroxyapatite: from synthesis to in vivo behaviour. J. Mater. Sci. Mater. Med. 2008, 19:239-247.
43. Coulombe J., et al. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem. Biophys. Res. Commun. 2004, 323:1184-1190.
44. Brown E.M. Is the calcium receptor a molecular target for the actions of strontium on bone?. Osteoporos. Int. 2003, 14:25-34.
45. Tat S.K., et al. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone 2011, 49:559-567.
46. Kostenuik P.J., Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr. Pharm. Des. 2001, 7:613-635.
47. Saidak Z., Marie P.J. Strontium signaling: molecular mechanisms and therapeutic implications in osteoporosis. Pharmacol. Ther. 2012, 136:216-226.
48. Meunier P.J., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 2004, 350:459-468.
49. Ni G., et al. Strontium-containing hydroxyapatite bioactive bone cement in revision hip arthroplasty. Biomaterials 2006, 27:4348-4355.
50. Chen Y.W., et al. Interaction of endothelial cells with biodegradable strontium-doped calcium polyphosphate for bone tissue engineering. Appl. Surf. Sci. 2008, 255:331-335.
51. Tian M., et al. In vivo study of porous strontium-doped calcium polyphosphate scaffolds for bone substitute applications. J. Mater. Sci. Mater. Med. 2009, 20:1505-1512.
52. Barralet J., et al. Angiogenesis in calcium phosphate scaffolds by inorganic copper ion release. Tissue Eng. Part A 2009, 15:1601-1609.
53. Ewald A., et al. The effect of Cu(II)-loaded brushite scaffolds on growth and activity of osteoblastic cells. J. Biomed. Mater. Res. A 2012, 100A:2392-2400.
54. Gérard C., et al. The stimulation of angiogenesis and collagen deposition by copper. Biomaterials 2010, 31:824-831.
55. Wu C., et al. Copper-containing mesoporous bioactive glass scaffolds with multifunctional properties of angiogenesis capacity, osteostimulation and antibacterial activity. Biomaterials 2013, 34:422-433.
56. Stähli C., et al. Controlled copper ion release from phosphate-based glasses improves human umbilical vein endothelial cell survival in a reduced nutrient environment. Tissue Eng. Part A 2013, 19:548-557.
57. Sen C.K., et al. Copper-induced vascular endothelial growth factor expression and wound healing. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H1821-H1827.
58. Gaetke L.M., Chow C.K. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 2003, 189:147-163.
59. Jomova K., et al. Redox active metal-induced oxidative stress in biological systems. Transit. Met. Chem. 2012, 37:127-134.
60. Simonsen L.O., et al. Cobalt metabolism and toxicology-a brief update. Sci. Total Environ. 2012, 432:210-215.
61. Patntirapong S., et al. Effects of soluble cobalt and cobalt incorporated into calcium phosphate layers on osteoclast differentiation and activation. Biomaterials 2009, 30:548-555.
62. Wu C., et al. Hypoxia-mimicking mesoporous bioactive glass scaffolds with controllable cobalt ion release for bone tissue engineering. Biomaterials 2012, 33:2076-2085.
63. Fan W., et al. Enhancing in vivo vascularized bone formation by cobalt chloride-treated bone marrow stromal cells in a tissue engineered periosteum model. Biomaterials 2010, 31:3580-3589.
64. Ignjatović N., et al. Nanoparticles of cobalt-substituted hydroxyapatite in regeneration of mandibular osteoporotic bones. J. Mater. Sci. Mater. Med. 2013, 24:343-354.
65. 2 and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells. J. Cell Sci. 2006, 119:2667-2678.
66. Kim K.S., et al. A novel role of hypoxia-inducible factor in cobalt chloride- and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J. Immunol. 2006, 177:7211-7224.
67. Dzondo-Gadet M., et al. Action of boron at the molecular level: effects on transcription and translation in an acellular system. Biol. Trace Elem. Res. 2002, 85:23-33.
68. Studer D., et al. Molecular and biophysical mechanisms regulating hypertrophic differentiation in chondrocytes and mesenchymal stem cells. Eur. Cell Mater. 2012, 24:118-135.
69. Gorustovich A.A., et al. A histomorphometric study of alveolar bone modelling and remodelling in mice fed a boron-deficient diet. Arch. Oral Biol. 2008, 53:677-682.
70. Hakki S.S., et al. Boron enhances strength and alters mineral composition of bone in rabbits fed a high energy diet. J. Trace Elem. Med. Biol. 2012, 10.1016/j.jtemb.2012.07.001.
71. Jugdaohsingh R., et al. Increased longitudinal growth in rats on a silicon-depleted diet. Bone 2008, 43:596-606.
72. Nielsen F.H. Micronutrients in parenteral nutrition: boron, silicon, and fluoride. Gastroenterology 2009, 137:S55-S60.
73. Pietak A.M., et al. Silicon substitution in the calcium phosphate bioceramics. Biomaterials 2007, 28:4023-4032.
74. Carlisle E.M. Biochemical and morphological changes associated with long bone abnormalities in silicon deficiency. J. Nutr. 1980, 110:1046-1056.
75. Bergmann C., et al. 3D printing of bone substitute implants using calcium phosphate and bioactive glasses. J. Eur. Ceram. Soc. 2010, 30:2563-2567.
76. Kanazawa T., et al. Effects of additives on sintering and some properties of calcium phosphates with various Ca/P ratios. J. Mater. Sci. 1991, 26:417-422.
77. Hing K.A., et al. Effect of silicon level on rate, quality and progression of bone healing within silicate-substituted porous hydroxyapatite scaffolds. Biomaterials 2006, 27:5014-5026.
78. Patel N., et al. A comparative study on the in vivo behavior of hydroxyapatite and silicon substituted hydroxyapatite granules. J. Mater. Sci. Mater. Med. 2002, 13:1199-1206.
79. Jones J.R., et al. Extracellular matrix formation and mineralization on a phosphate-free porous bioactive glass scaffold using primary human osteoblast (HOB) cells. Biomaterials 2007, 28:1653-1663.
80. Xynos I.D., et al. Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem. Biophys. Res. Commun. 2000, 276:461-465.
81. Gomez-Vega J.M., et al. Bioactive glass coatings with hydroxyapatite and bioglass particles on Ti-based implants. 1. Processing. Biomaterials 2000, 21:105-111.
82. Reffitt D., et al. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Bone 2003, 32:127-135.
83. Li H., Chang J. Bioactive silicate materials stimulate angiogenesis in fibroblast and endothelial cell co-culture system through paracrine effect. Acta Biomater. 2013, 10.1016/j.actbio.2013.02.014.
84. 3/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways. Biomaterials 2013, 34:64-77.
85. Zhaojun W., et al. Effects of manganese deficiency on serum hormones and biochemical markers of bone metabolism in chicks. J. Bone Miner. Metab. 2013, 10.1007/s00774-012-0417-6.
86. Lüthen F., et al. Influence of manganese ions on cellular behavior of human osteoblasts in vitro. Biomol. Eng. 2007, 24:531-536.
87. Lewiecki E.M., Miller P.D. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. J. Clin. Densitom. 2013, 16:28-32.
88. Filaire E., Toumi H. Reactive oxygen species and exercise on bone metabolism: friend or enemy?. Joint Bone Spine 2012, 79:341-346.
89. Wauquier F., et al. Oxidative stress in bone remodelling and disease. Trends Mol. Med. 2009, 15:468-477.
90. Paluszkiewicz C., et al. Synthesis, structural properties and thermal stability of Mn-doped hydroxyapatite. J. Mol. Struct. 2010, 976:301-309.
91. Sopyan I., et al. Effects of manganese doping on properties of sol-gel derived biphasic calcium phosphate ceramics. Ceram. Int. 2011, 37:3703-3715.
92. Bracci B., et al. Effect of Mg(2+), Sr(2+), and Mn(2+) on the chemico-physical and in vitro biological properties of calcium phosphate biomimetic coatings. J. Inorg. Biochem. 2009, 103:1666-1674.
93. 2 doped β-TCP. Bone 2011, 48:1282-1290.
94. Roy M., et al. Effects of zinc and strontium substitution in tricalcium phosphate on osteoclast differentiation and resorption. Biomater. Sci. 2012, 1:74-82.
95. Tarafder S., et al. 3D printed tricalcium phosphate bone tissue engineering scaffolds: effect of SrO and MgO doping on in vivo osteogenesis in a rat distal femoral defect model. Biomater. Sci. 2013, 10.1039/c3bm60132c.
96. 2 and ZnO dopants in 3D printed TCP scaffolds enhances osteogenesis and angiogenesis in vivo. Acta Biomater. 2013, in press. 10.1016/j.actbio.2013.07.009.
97. Tarafder S., et al. Effect of electrical polarization and composition of biphasic calcium phosphates on early stage osteoblast interactions. J. Biomed. Mater. Res. B: Appl. Biomater. 2011, 97:306-314.
98. Bodhak S., et al. Influence of MgO, SrO, and ZnO dopants on electro-thermal polarization behavior and in vitro biological properties of hydroxyapatite ceramics. J. Am. Ceram. Soc. 2011, 94:1281-1288.
99. Zreiqat H., et al. The incorporation of strontium and zinc into a calcium-silicon ceramic for bone tissue engineering. Biomaterials 2010, 31:3175-3184.
100. Laurencin D., et al. Magnesium incorporation into hydroxyapatite. Biomaterials 2011, 32:1826-1837.
101. Bohner M. Silicon-substituted calcium phosphates - a critical view. Biomaterials 2009, 30:6403-6406.